$RENB
RENOVARO INC. Stock $renb

$renb Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000173112223002120 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.616M	$8.290M	$4.557M
YoY Change	-9.88%	81.92%	2.02%
% of Gross Profit
Research & Development	$620.5K	$566.6K	$2.605M
YoY Change	90.37%	-78.25%	-13.33%
% of Gross Profit
Depreciation & Amortization	$33.16K	$27.26K	$28.40K
YoY Change	14.97%	-4.02%	-10.49%
% of Gross Profit
Operating Expenses	$4.270M	$8.884M	$7.191M
YoY Change	-2.24%	23.55%	-4.18%
Operating Profit	-$4.270M	-$8.884M	-$7.191M
YoY Change	-2.24%	23.55%	-4.18%
Interest Expense	-$259.0K	-$170.0K	$95.59K
YoY Change	-378.86%	-277.85%	-215.69%
% of Operating Profit
Other Income/Expense, Net	-$259.0K	-$290.9K	-$509.1K
YoY Change	188.21%	-42.86%	-81.97%
Pretax Income	-$4.529M	-$9.175M	-$7.700M
YoY Change	1.6%	19.16%	-26.05%
Income Tax
% Of Pretax Income
Net Earnings	-$4.529M	-$9.175M	-$7.700M
YoY Change	1.6%	19.16%	-26.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.07	-$0.14	-$0.14
Diluted Earnings Per Share	-$0.07	-$0.14	-$0.14
COMMON SHARES
Basic Shares Outstanding	66.70M shares	65.70M shares	55.10M shares
Diluted Shares Outstanding	65.85M shares	64.48M shares	55.10M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$244.0K	$500.0K	$7.972M
YoY Change	-94.08%	-93.73%	-48.16%
Cash & Equivalents	$244.0K	$523.5K	$7.972M
Short-Term Investments
Other Short-Term Assets	$1.086M	$300.0K	$160.6K
YoY Change	-14.56%	86.76%	105.65%
Inventory
Prepaid Expenses
Receivables	$1.074M	$1.100M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.403M	$1.906M	$8.133M
YoY Change	-55.41%	-76.56%	-47.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$496.9K	$482.5K	$559.6K
YoY Change	-10.62%	-13.78%	-72.89%
Goodwill	$11.64M	$11.64M	$11.64M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$55.12M	$55.17M	$74.38M
YoY Change	-25.85%	-25.82%	354420.44%
Total Long-Term Assets	$55.61M	$55.66M	$74.94M
YoY Change	-25.73%	-25.73%	-55.56%
TOTAL ASSETS
Total Short-Term Assets	$2.403M	$1.906M	$8.133M
Total Long-Term Assets	$55.61M	$55.66M	$74.94M
Total Assets	$58.02M	$57.56M	$83.07M
YoY Change	-27.72%	-30.71%	-54.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.578M	$5.400M	$4.683M
YoY Change	22.45%	15.32%	754.72%
Accrued Expenses	$783.6K	$797.8K	$1.042M
YoY Change	-15.98%	-23.46%	57.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.509M	$3.700M	$1.200M
YoY Change	37.72%	208.33%
Total Short-Term Liabilities	$13.76M	$10.10M	$7.159M
YoY Change	21.84%	41.02%	491.4%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$4.652M
YoY Change	-100.0%	-100.0%	-20.53%
Other Long-Term Liabilities	$664.2K	$700.0K	$934.9K
YoY Change	-24.72%	-25.12%	-90.68%
Total Long-Term Liabilities	$664.2K	$720.8K	$5.587M
YoY Change	-68.1%	-87.1%	-64.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.76M	$10.10M	$7.159M
Total Long-Term Liabilities	$664.2K	$720.8K	$5.587M
Total Liabilities	$14.42M	$10.82M	$12.75M
YoY Change	7.84%	-15.14%	-25.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$257.7M	-$253.2M	-$212.0M
YoY Change	19.04%	19.41%
Common Stock	$6.724K	$6.571K	$5.552K
YoY Change	20.67%	18.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.60M	$46.75M	$70.32M
YoY Change
Total Liabilities & Shareholders Equity	$58.02M	$57.56M	$83.07M
YoY Change	-27.72%	-30.71%	-54.87%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$4.529M	-$9.175M	-$7.700M
YoY Change	1.6%	19.16%	-26.05%
Depreciation, Depletion And Amortization	$33.16K	$27.26K	$28.40K
YoY Change	14.97%	-4.02%	-10.49%
Cash From Operating Activities	-$3.144M	-$2.777M	-$2.820M
YoY Change	-7.12%	-1.53%	-46.55%
INVESTING ACTIVITIES
Capital Expenditures	$41.58K
YoY Change	75.96%
Acquisitions
YoY Change
Other Investing Activities	-$13.63K	-$1.060M	$0.00
YoY Change
Cash From Investing Activities	-$55.21K	-$1.058M
YoY Change	133.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.850M	$2.563M	$1.625M
YoY Change	-710.71%	57.71%
NET CHANGE
Cash From Operating Activities	-3.144M	-$2.777M	-$2.820M
Cash From Investing Activities	-55.21K	-$1.058M
Cash From Financing Activities	2.850M	$2.563M	$1.625M
Net Change In Cash	-349.4K	-$1.351M	-$1.200M
YoY Change	-90.98%	12.56%	-77.28%
FREE CASH FLOW
Cash From Operating Activities	-$3.144M	-$2.777M	-$2.820M
Capital Expenditures	$41.58K
Free Cash Flow	-$3.185M		-$2.820M
YoY Change	-6.54%		-46.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001527728
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	RENB	Restricted Shares For Services Rendered RestrictedSharesForServicesRendered		usd
CY2023Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
CY2023Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
CY2022Q3	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q3	RENB	Proceeds From Issuance Of Convertible Promissory Notes ProceedsFromIssuanceOfConvertiblePromissoryNotes		usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q3	RENB	Conversion Of Note Payable For Issuance Of Preferred Stock ConversionOfNotePayableForIssuanceOfPreferredStock		usd
CY2023Q3	RENB	Common Shares Issued For Contingent Earn Out Liability CommonSharesIssuedForContingentEarnOutLiability		usd
CY2022Q3	RENB	Debt Discount Related To Convertible Promissory Notes DebtDiscountRelatedToConvertiblePromissoryNotes		usd
CY2023Q3	RENB	Period Change PeriodChange		usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome		usd
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	001-38758
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	Renovaro Biosciences Inc.
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2559340
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	2080 Century Park East
CY2023Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 906
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2023Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90067
CY2023Q3	dei	City Area Code CityAreaCode	(305)
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	918-1980
CY2023Q3	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q3	dei	Trading Symbol TradingSymbol	RENB
CY2023Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	66698144	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	523474	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1874480	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	1057875	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	324966	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	690925	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1906315	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2565405	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	482510	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508989	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37641	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	11640000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	11640000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	21742	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	21741	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	863598	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244029253	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-64483	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29882	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	46746312	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46502111	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57562806	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	913985	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55173981	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55226402	usd
CY2023Q3	us-gaap	Assets Assets	57562806	usd
CY2023Q2	us-gaap	Assets Assets	58300796	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5421126	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5296823	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	797778	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	723173	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	184733	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	214061	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	193422	usd
CY2023Q3	RENB	Notes Payable Net NotesPayableNet	2909987	usd
CY2023Q2	RENB	Notes Payable Net NotesPayableNet	4624947	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	752741	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10095693	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11023098	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	720801	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	775587	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	720801	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	775587	usd
CY2023Q3	us-gaap	Liabilities Liabilities	10816494	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11798685	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	561010	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	561010	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	56	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65698144	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65698144	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63698144	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63698144	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	6571	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6371	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	300008449	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290554875	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253204281	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58300796	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8290210	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4556840	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	566644	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2605375	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27260	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28401	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	8884114	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	7190616	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8884114	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7190616	usd
CY2023Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-120018	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419182	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	179271	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	95585	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	8375	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5623	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290914	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-509144	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9175028	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7699760	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9175028	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64480753	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64480753	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55099473	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55099473	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9175028	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	34601	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	7754	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9209629	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7707514	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	72618848	usd
CY2022Q3	RENB	Stock Issued Pursuant To Warrants Exercised Value StockIssuedPursuantToWarrantsExercisedValue	1625000	usd
CY2022Q3	RENB	Shares Issued For Earnout SharesIssuedForEarnout	2762500	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1026008	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7754	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	70324842	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46502111	usd
CY2023Q3	RENB	Issuance Of Preferred Stock And Warrants In Private Placement IssuanceOfPreferredStockAndWarrantsInPrivatePlacement	2000000	usd
CY2023Q3	RENB	Issuance Of Preferred Stock And Warrants For Conversion2 Million Note IssuanceOfPreferredStockAndWarrantsForConversion2MillionNote	2000001	usd
CY2023Q3	RENB	Restricted Shares Issued For Services Rendered Value RestrictedSharesIssuedForServicesRenderedValue	4470000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	983829	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9175028	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-34601	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	46746312	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9175028	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27260	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28401	usd
CY2023Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-120018	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419182	usd
CY2023Q3	RENB	Non Cash Compensation NonCashCompensation	983829	usd
CY2022Q3	RENB	Non Cash Compensation NonCashCompensation	1026008	usd
CY2023Q3	RENB	Restricted Shares For Services Rendered RestrictedSharesForServicesRendered	4470000	usd
CY2023Q3	RENB	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	167765	usd
CY2022Q3	RENB	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	74621	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3988	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-411352	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-239703	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	124303	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3280877	usd
CY2023Q3	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	77055	usd
CY2022Q3	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10783	usd
CY2022Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-18520	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	16239	usd
CY2022Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10981	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2777207	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2653674	usd
CY2023Q3	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1057875	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1057875	usd
CY2023Q3	RENB	Proceeds From Issuance Of Convertible Promissory Notes ProceedsFromIssuanceOfConvertiblePromissoryNotes	750000	usd
CY2023Q3	RENB	Repayment Of Finance Agreement RepaymentOfFinanceAgreement	187183	usd
CY2022Q3	RENB	Repayment Of Finance Agreement RepaymentOfFinanceAgreement	166625	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2000000	usd
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1625000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2562817	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1458375	usd
CY2023Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-78741	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4925	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1351006	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1200224	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1874480	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9172142	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	523474	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7971918	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	5256	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	30332	usd
CY2023Q3	RENB	Conversion Of Note Payable For Issuance Of Preferred Stock ConversionOfNotePayableForIssuanceOfPreferredStock	2000001	usd
CY2022Q3	RENB	Common Shares Issued For Contingent Earn Out Liability CommonSharesIssuedForContingentEarnOutLiability	2762500	usd
CY2023Q3	RENB	Debt Discount Related To Convertible Promissory Notes DebtDiscountRelatedToConvertiblePromissoryNotes	39474	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253204281	usd
CY2023Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z8qaCBVVwMh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_863_z0TVCB6qpttj">Accounting Estimates</span> –</b> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2023Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	144568	usd
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1526990	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18960000	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	11640000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	566644	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2605375	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17136596	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4495477	shares
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	419182	usd
CY2022Q3	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	9380	usd
CY2023Q3	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	61223	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	983829	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1026008	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9175028	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	523474	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253204281	usd
CY2023Q3	RENB	Promissory Notes Amount PromissoryNotesAmount	550000	usd
CY2023Q3	RENB	Promissory Notes Amount PromissoryNotesAmount	500000	usd
CY2023Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	1050000.00	usd
CY2023Q3	RENB	Accrued Interest Rate AccruedInterestRate	0.06	pure
CY2023Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	7875	usd
CY2023Q3	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1057875	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	973788	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	973788	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	491278	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	464799	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	482510	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508989	usd
CY2023Q3	us-gaap	Depreciation Depreciation	26479	usd
CY2022Q3	us-gaap	Depreciation Depreciation	26915	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37641	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	781	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1486	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2023Q3	RENB	Finite Lived Intangible Assets Period Change FiniteLivedIntangibleAssetsPeriodChange	-781	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-1254	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37641	usd
CY2023Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	54251000	usd
CY2023Q3	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	54251000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7059	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10194	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10194	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	10194	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37641	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	53310	usd
CY2023Q3	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	-68743	usd
CY2022Q3	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	9380	usd
CY2023Q3	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	-68743	usd
CY2017Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized.
CY2018Q2	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M1D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0403	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	185403	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	253384	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	260985	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	268815	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	45021	usd
CY2023Q3	RENB	Lessee Operating Lease Liability Sub Total Amount LesseeOperatingLeaseLiabilitySubTotalAmount	-1013608	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	78746	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	934862	usd
CY2022Q2	us-gaap	Lessee Finance Sublease Residual Value Guarantee Description LesseeFinanceSubleaseResidualValueGuaranteeDescription	On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
CY2023Q2	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	139460	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	35540	usd
CY2023Q2	us-gaap	Liabilities Subject To Compromise Early Contract Termination Fees LiabilitiesSubjectToCompromiseEarlyContractTerminationFees	175000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	68743	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	43930	usd
CY2022Q3	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	144461	usd
CY2023Q3	RENB	Debt Instrument Original Issue Discount DebtInstrumentOriginalIssueDiscount	0.05	pure
CY2023Q3	RENB	Debt Instrument Original Issue Discount DebtInstrumentOriginalIssueDiscount	0.05	pure
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	789474	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	789474	usd
CY2023Q3	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2023Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-09-05
CY2023Q3	RENB	Common Stock And Receives Gross Proceeds CommonStockAndReceivesGrossProceeds	10000000	usd
CY2023Q3	RENB	Offering Price Per Share Percentage OfferingPricePerSharePercentage	0.95	pure
CY2023Q3	RENB	Debt Instruments Floor Of Per Share DebtInstrumentsFloorOfPerShare	4.50
CY2023Q3	RENB	Debt Instruments Floor Of Per Share DebtInstrumentsFloorOfPerShare	4.50
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	789474	usd
CY2023Q3	RENB	Proceeds From Received Amount ProceedsFromReceivedAmount	750000	usd
CY2023Q3	RENB	Debt Instrument Original Issue Discount DebtInstrumentOriginalIssueDiscount	0.05	pure
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	39474	usd
CY2023Q3	RENB	Debt Instrumentadditional Face Amount DebtInstrumentadditionalFaceAmount	1250000	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2741	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	6250	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	752741	usd
CY2022Q4	RENB	Prepayment Shares PrepaymentShares	169020	shares
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	204392	usd
CY2022Q4	us-gaap	Prepaid Interest PrepaidInterest	174090	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	30302	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1200000	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	12030	usd
CY2023Q3	RENB	Amended And Restated Secured Notes Balance AmendedAndRestatedSecuredNotesBalance	0	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	47115	shares
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	299178	usd
CY2022Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1139875	usd
CY2022Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.0669	pure
CY2022Q4	RENB	Monthly Installments MonthlyInstallments	96220	usd
CY2022Q4	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	300000	usd
CY2023Q3	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	187183	usd
CY2022Q3	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	166625	usd
CY2023Q3	RENB	Interest Expense Related Parties InterestExpenseRelatedParties	5256	usd
CY2022Q3	RENB	Interest Expense Related Parties InterestExpenseRelatedParties	2782	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	179271	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	95585	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65698144	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65698144	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63698144	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63698144	shares
CY2022Q2	us-gaap	Purchase Obligation PurchaseObligation	20000000	usd
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	0	shares
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	983829	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1026008	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1305630	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3409891	usd
CY2018Q3	RENB	Consulting Expenses ConsultingExpenses	130000	usd
CY2019Q4	RENB	Upfront Payment UpfrontPayment	10000000	usd
CY2019Q4	RENB	Payment For Expenditures PaymentForExpenditures	760000	usd
CY2021Q3	RENB	Initial Payment InitialPayment	600000	usd
CY2021Q3	RENB	Paid Initial Payment PaidInitialPayment	600000	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The Company maintains employment agreements with other staff in the ordinary course of business.
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.13
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	2000000	usd
CY2023Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	280505	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.13

Files In Submission

Name	View Source	Status
0001731122-23-002120-index-headers.html	Edgar Link	pending
0001731122-23-002120-index.html	Edgar Link	pending
0001731122-23-002120.txt	Edgar Link	pending
0001731122-23-002120-xbrl.zip	Edgar Link	pending
e5207_10q.htm	Edgar Link	pending
e5207_ex10-3.htm	Edgar Link	pending
e5207_ex31-1.htm	Edgar Link	pending
e5207_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
renb-20230930_cal.xml	Edgar Link	unprocessable
renb-20230930_pre.xml	Edgar Link	unprocessable
e5207_ex31-2.htm	Edgar Link	pending
e5207_ex32-1.htm	Edgar Link	pending
e5207_ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
renb-20230930.xsd	Edgar Link	pending
renb-20230930_def.xml	Edgar Link	unprocessable
renb-20230930_lab.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RENB
RENOVARO INC. Stock $renb

2023 Q4 Form 10-Q Financial Statement

#000173112223002120 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB RENOVARO INC. Stock $renb

2023 Q4 Form 10-Q Financial Statement

#000173112223002120 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB
RENOVARO INC. Stock $renb